Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific

Ruth Levitz1, Rachel Wattier3,4, Pamela Phillips1, Alexandra Solomon1, Jessica Lawler1, Isaac Lazar3,5, Carla Weibel3 and Jeffrey S Kahn1,2*

Abstract

Background: Respiratory syncytial virus (RSV) is the major respiratory pathogen of infants and young children. During each seasonal epidemic, multiple strains of both subgroup A and B viruses circulate in the community. Like other RNA viruses, RSV genome replication is prone to errors that results in a heterogeneous population of viral strains some of which may possess differences in virulence. We sought to determine whether clinical isolates of RSV differ in their capacity to induce inflammatory cytokines IL-6 and CCL5 (previously known as RANTES [regulated upon activation, normal T-cell expressed and secreted protein]), which are known to be induced in vitro and in vivo in response to RSV, during infection of A549 cells.

Results: Screening of subgroup A and B isolates revealed heterogeneity among strains to induce IL-6 and CCL5. We chose two subgroup B strains, New Haven (NH)1067 and NH1125, for further analysis because of their marked differences in cytokine inducing properties and because subgroup B strains, in general, are less genetically heterogeneous as compared to subgroup A strains. At 12 and 24 hours post infection RSV strains, NH1067 and NH1125 differed in their capacity to induce IL-6 by an order of magnitude or more. The concentrations of IL-6 and CCL5 were dependent on the dose of infectious virus and the concentration of these cytokines induced by NH1125 was greater than that of those induced by NH1067 when the multiplicity of infection of NH1067 used was as much as 10-fold higher than that of NH1125. The induction of IL-6 was dependent on viable virus as infection with UV-inactivated virus did not induce IL-6. The difference in IL-6 induction most likely could not be explained by differences in viral replication kinetics. The intracellular level of RSV RNA, as determined by quantitative RT-PCR, was indistinguishable between the 2 strains though the titer of progeny virus produced by NH1125 was greater than that produced by NH1067 at 16, 24 and 36 hours but essentially equal at 48 and 72 hours. Full genome sequencing of the 2 strains revealed 193 polymorphisms and 4 insertions in NH1067 when compared to NH1125 (2 single base insertions in non-coding regions and 2 duplications of 3 and 60 bases in the RSV G gene). Of the polymorphisms, 147 occurred in coding regions and only 30 resulted in amino acid changes in 7 of the RSV genes.

(Continued on next page)
Conclusions: These data suggest that RSV strains may not be homogeneous with regard to pathogenesis or virulence. Identification of the genetic polymorphisms associated with variations in cytokine induction may lead to insights into RSV disease and to the development of effective antiviral agents and vaccines.

Keywords: Respiratory syncytial virus, Clinical isolates, IL-6, RANTES, CCL5, Respiratory syncytial virus genome

Background
Respiratory syncytial virus (RSV) is a major respiratory pathogen of infants and young children as well as the elderly and immunocompromised populations [1]. Clinical isolates can be categorized into 1 of 2 major subgroups of RSV, A or B, by immunological or genetic methods [2,3]. Within each subgroup, there are several distinct genotypes, a variety of which co-circulate during yearly epidemics [3-5].

The inflammatory response to RSV infection plays a major role in the disease pathogenesis and this inflammation may result in signs of restrictive and obstructive lung disease long after RSV can be detected in respiratory secretions. RSV elicits the production of a variety of cytokines and chemokines during and after infection [6,7]. Both in vivo and in vitro data suggest that IL-6, a pro-inflammatory cytokine, is a key component of the response of the host to RSV infection. Microarray analysis of RSV-infected human alveolar type II epithelial (A549) cells reveals that IL-6 mRNA was induced ~20-fold 30 minutes after infection [8]. IL-6 is present in the respiratory secretions of RSV-infected individuals and serum levels of IL-6 are increased during RSV infection [9,10]. The mechanism by which RSV induces IL-6 production is poorly understood. The chemokine CCL5 (previously known as RANTES [regulated upon activation, normal T-cell expressed and secreted protein]) is induced in humans and animal models of RSV and evidence suggests that this molecule plays an important role in pathogenesis [6,11]. Therefore, exploration of the induction of IL-6 and CCL5 by clinical isolates of RSV may be insightful.

Several groups, including our own, have demonstrated a potential association between viral genotype and severity of illness, suggesting that clinical isolates of RSV may differ in virulence [9,12-15]. However, the study of strain-specific factors in vivo is complicated by a variety of host factors influencing the severity of infection. In order to eliminate these factors, we chose to study strain differences in a cell culture model system. As such, we screened and plaque purified clinical isolates of RSV and assessed their ability to induce cytokines in human alveolar type II epithelial (A549) cells. The results demonstrate that clinical isolates differ dramatically in their ability to induce certain cytokines in cell culture. These findings suggest that the genetic variability of clinical isolates of RSV may contribute to the severity of infection caused by the virus.

Figure 1 Screening of clinical isolates of RSV for induction of IL-6. A549 cells were infected with multiplicity of infection (moi) 1 and IL-6 concentrations in cell culture supernatants at 24 hours post infection were measured by ELISA. Subgroup A isolates (clades GA2, GA3 and GA4) and subgroup B isolates are designated by the bars below the graph. Subgroup B isolates NH1067 and NH1125, chosen for subsequent experiments, are boxed.
Results
Screening of clinical isolates of RSV for their ability to induce IL-6
Since 1998, we have propagated clinical strains of RSV in cell culture and have performed phylogenetic analysis of >200 of these isolates (data not shown). From this collection of clinical isolates, we screened both subgroup A and B isolates for their ability to induce the secretion of IL-6 during infection of the pulmonary epithelial cell line A549. We chose genetically diverse strains of subgroup A (representing at least 3 distinct clades [12]) and B isolates (based on previous phylogenetic analysis (data not shown). The strains screened were not homogenous in their cytokine induction properties (Figure 1). To further explore this phenomenon, we chose 2 subgroup B strains, New Haven (NH)1067 and NH1125 for further investigation. These strains were chosen for 2 reasons: 1) there were marked differences observed in the levels of IL-6 induced between these strains (Figure 1, boxed) and; 2) subgroup B isolates are less genetically heterogeneous as compared to subgroup A isolates. Our hypothesis was that there would be fewer polymorphisms between pairs of isolates of subgroup B as compared to subgroup A. If so, study of subgroup B isolates would be preferable in eventually identifying the viral genetic markers responsible for cytokine induction. Both strains were isolated from respiratory specimens collected in 2002. At 12 and 24 hours post-infection, the level of IL-6 induced by NH1125 was at least an order of magnitude greater than that by NH1067 (Figure 2). The mechanism of this induction was explored. UV-inactivated virus (both strains) failed to induce IL-6 (Figure 2) suggesting that viable virus, or at least virus with transcriptional and genome replication activity was required for induction of IL-6. These findings also suggest that virus binding to the target cell, which presumably still occurs with UV-inactivated virus, was not sufficient for IL-6 induction.

Dynamics of replication of clinical isolates NH1067 and NH1125
One potential explanation for the observed differences in cytokine induction by NH1067 and NH1125 was that the replication kinetics of the 2 viruses differed. To address this possibility, viral replication kinetics were assayed by 2 means: quantitative real time PCR and traditional viral growth assays. Quantitative RT-PCR, using primers specific for the negative sense genome strand, revealed that the kinetics of genome replication of NH1125 and NH1067 were identical (Figure 3). As shown in Figure 4, production of infectious virus from NH1067- or NH1125-infected cells at 48 and 72 hours post-infection are identical though at earlier times, there is less infectious virus detected in NH1067-infected cells.

Induction of cytokines is dose-dependent
To further explore the differences in cytokine induction by strains NH1067 and NH1125, infectious dose–response experiments were performed. A549 cells were infected with a multiplicity of infection (moi) of 0.013, 0.04 or 0.13 and supernatant levels of IL-6 and CCL5 were determined at 24 hours post-infection. As shown in Figure 5 (a and b), induction of IL-6 and CCL5 by NH1125 was dependent on the infectious dose of virus.
There also appeared to be a dose-dependent induction of CCL5 in cells infected with NH1067. However, NH1067 was a comparatively very poor inducer of both cytokines. Of note, the levels of IL-6 and CCL5 induced by NH1067 at a moi of 0.13 was essentially equivalent to the levels of IL-6 and CCL5 induced by NH1125 at a moi of 0.013, a ten-fold difference in infectious dose.

Genome sequence comparisons of NH1067 and NH1125
The genome of NH1067 contained 15,283 nucleotides [GenBank: accession JQ582844] and the genome of NH1125 contained 15,216 nucleotides [GenBank: accession JQ582843]. Overall, there were 194 polymorphisms between the 2 viruses (Table 1). Nucleotide differences were observed in every open reading frame (ORF) though the majority (117/147) of the polymorphisms in the coding sequences were synonymous. The exception was the RSV G gene. Of the 23 polymorphisms detected in the RSV G gene of NH1067 and NH1125, 13 resulted in mis-sense mutations while 10 were silent. This is not surprising as the RSV G gene is known to be the most variable of all genes in the RSV genome [16,17]. The RSV G gene of NH1067 contained 2 duplications, 3 and 60 nucleotides in length, which were not present in NH1125. Viruses containing the 60 base duplication were first identified in Buenos Aires in 1999 [18]. Subsequently, RSV subgroup B viruses with this 60 base insertion have been identified worldwide [19].

Association of genotype and cytokine induction phenotype
To determine whether other subgroup B isolates had cytokine-inducing phenotypes similar to NH1067 or NH1125, 8 additional viruses were assayed for their ability to induce IL-6 and CCL5. These additional viruses were chosen because they were NH1067-like, NH1125-like or distantly related to NH1067 and NH1125 based on their G gene sequences some of which contained the 60-base duplication. As shown in Figure 6, the induction profiles correlated, for the most part, with genotype. NH1001 and NH1125 had similar cytokine induction profiles and were closely related genetically. Likewise, NH1067, Texas (TX)11-56 and NH1182, closely related viruses, were poor cytokine inducers (low inducers). However, NH1161, a relative outlier, had an IL-6 induction phenotype that was similar to NH1001. Of note, the low induction phenotype does not seem to correlate with the G gene duplication detected in NH1067. Viruses containing the 60 base duplication (NH1067, NH1182, TX11-56; designated with the * in Figure 5) and viruses lacking this duplication (NH923, NH1144, NH1262, NH1276) all had a low induction phenotype. Polymorphisms in the F gene in NH1067 and NH1125 resulted in 4 amino acid differences at positions 67, 292, 490 and 529. It is unlikely that any of these 4 mutations were the basis for the observed phenotype. Sequencing of the F gene of the viruses represented in Figure 5 did
not reveal a correlation between specific amino acid residues at these positions in the F protein and cytokine induction phenotype (data not shown).

Discussion
RSV elicits the production of a wide variety of cytokines and chemokines during and after infection [6,7,20-23]. There is now mounting evidence that the type of immune response to RSV, specifically the spectrum of host cytokine and chemokine production, ultimately affects disease pathogenesis and chronicity [6]. Cytokine expression likely affects the balance between viral clearance and progression of disease. Therefore, there is a critical need to identify viral factors that regulate cytokine expression during RSV infection [6].

The vast majority of studies into RSV pathogenesis have used laboratory strains or recombinant virus derived from these laboratory strains. These laboratory strains were isolated decades ago and the passage histories of these strains are not known or are poorly documented. Several studies suggest that sole investigation of laboratory strains may not be ideal to define and characterize RSV pathogenesis. For example, Line 19, a potential vaccine strain derived from a subgroup A isolate possesses biological features that differ from the reference strain A2 (isolated in Australia in 1961) [24]. These phenotypic differences have been mapped to polymorphisms in the RSV F gene [25]. Reference strain A2 differs from several clinical isolates in its ability to replicate on primary human bronchial epithelial cells and to induce interferon-inducible protein 10 and CCL5 suggesting that A2 alone may not be the ideal strain to study RSV pathogenesis [26]. Recently, Stokes et al. demonstrated that several clinical isolates differ in their capacity to induce airway mucous production and virulence in mice [27]. Therefore, the study of clinical isolates will likely yield important insights into the fundamental aspects of pathogenesis.

At least 2 RSV proteins have been implicated in the induction of IL-6, RSV F and G. In monocytes, RSV F

| Genomic segment | Length in bases | Nucleotide differences | Non-sense | Mis-sense | Silent |
|-----------------|----------------|------------------------|-----------|-----------|--------|
| 3'end-NS1       | 98             | 1                      |           |           |        |
| NS1 gene       | 420            | 1                      |           |           |        |
| NS1-NS2        | 107            | 0                      |           |           |        |
| NS2 gene       | 375            | 4                      | 1         | 3         |        |
| NS2-N          | 136 (137)      | 6                      |           |           |        |
| N gene         | 1176           | 16                     | 1         | 15        |        |
| N-P            | 32             | 0                      |           |           |        |
| P gene         | 726            | 5                      | 1         | 4         |        |
| P-M            | 186 (188)      | 11                     |           |           |        |
| M gene         | 771            | 10                     |           |           | 10     |
| M-SH           | 268            | 10                     |           |           |        |
| SH gene        | 198            | 4                      |           |           | 4      |
| SH-G           | 189            | 4                      |           |           |        |
| G gene         | 888 (951)      | 23                     | 13        | 10        |        |
| G-F            | 88             | 0                      |           |           |        |
| F gene         | 1725           | 20                     | 4         | 16        |        |
| F-M2-1         | 225 (226)      | 8                      |           |           |        |
| M2-1 gene      | 588            | 4                      | 2         | 2         |        |
| M2-1-M2-2d     | 35             | 0                      |           |           |        |
| M2-2 gene      | 273            | 4                      |           |           | 4      |
| M2-2-L         | 65             | 2                      |           |           |        |
| L gene         | 6501           | 59                     | 8         | 51        |        |
| L-5'end        | 216            | 2                      |           |           |        |
| Total          | 15216 (15283)  | 194                    | 0         | 30        | 120    |

*aGene coding sequences ("gene") or intergenic (inter-ORF) segment listed unless otherwise noted (3' and 5' end).
*bNH1067 length in () when it differs from NH1125. NH1067 G gene contains a 3 base and 60 base insertion.
*cNon-sense, mis-sense and silent nucleotide differences between the 2 strains are listed for coding sequences only.
*dM2-1 and M2-2 overlap by 35 nucleotides.
stimulates IL-6 through interactions with CD14+/TLR4 complex by promoting nuclear translocation of NF-κB [28]. IL-6, along with other cytokines, such as IL-1β and IL-8, play an important role in neutrophil and macrophage chemotaxis. The cellular inflammatory response during severe RSV infection is characterized by a preponderance of neutrophils and macrophages, suggesting that the expression of IL-6 at the site of infection is an essential feature in disease progression [29]. Differences in IL-6 induction may explain, in part, differences in severity of illness seen with RSV infection. Indeed, clinical studies of both infants and adults have demonstrated that single nucleotide polymorphisms in the IL-6 promoter (position −174) were associated with a greater severity of illness suggesting a pivotal role of IL-6 in RSV pathogenesis [30,31]. Our data suggests that variability in the induction of IL-6 may, at least, partially explain differences in the observed severity of human RSV disease associated with infection due to specific RSV genotypes [9,12-15]. The RSV F protein of NH1067 and NH1125 differs at only 4 amino acid residues (positions 67, 292, 490 and 529). It did not appear that these amino acid changes can account for the differences in induction of IL-6 observed because the specific amino acid residues at these positions did not correlate to induction phenotype when other strains were examined.

Several lines of evidence indicate that the RSV G glycoprotein also plays a role in pathogenesis and can induce IL-6 among other cytokines [32-37]. Monocyte stimulation experiments using recombinant viruses with altered or absent G gene and synthetic peptides, corresponding to regions of the RSV G protein, revealed that portions of the highly conserved cysteine-rich region, specifically amino acids 164–176, inhibit the innate immune response [37]. The CX3C motif (amino acid 182–186) of the RSV G glycoprotein mimics the CX3C chemokine fractalkine, competes for the chemokine-specific receptor and interferes with fractalkine-mediated leukocyte chemotaxis [32]. RSV deficient in the soluble form of G (generated by initiation at the second AUG corresponding to amino acid 48) induced a pro-inflammatory response in A549 cells [38]. Amino acids 164–176 and 182–186 were identical in NH1067 and NH1125. Both strains contained a methionine at position 48. Therefore, these regions of the RSV G gene, although likely important for cytokine induction pathways, cannot account for the differences observed in IL-6 induction between NH1067 and NH1125.

Our data suggest that the differences in the RSV F protein between NH1067 and NH1125 are unlikely to account for the differences in cytokine induction phenotype strongly suggesting that other viral factors, perhaps
in other domains of the G protein, may play a role in the differences in cytokine induction observed in the clinical isolates. These factors may not necessarily be viral proteins. A single nucleotide substitution in the transcriptional start signal of the M2 gene, within a non-coding region of the RSV genome [39] is the major determinant of the temperature-sensitive, attenuated phenotype of a potential vaccine candidate. However, the consensus transcriptional start and stop signals for each gene were identical between NH1067 and NH1125. It appears as though viral transcriptional and/or replication activity rather than binding of virion-associated glycoproteins to cellular receptors is required as UV-inactivated virus failed to induce IL-6, an observation that has been reported elsewhere [40,41].

RSV causes a wide-spectrum of disease and this may be due, in part, to the differences in biological properties of the infecting virus. This phenomenon has been observed with other viruses. For example, mutations in the HCV NS5A gene are associated with a sustained virological response to interferon therapy [42]. A neurotropic variant of HIV, containing a mutation in the envelope gene, has been identified, which is present at a high frequency in brain tissue in AIDS patients with dementia [43]. Mutations in several genes may account for the increased virulence of the 1918 influenza pandemic strain [44]. Identification of the viral gene(s) involved in the induction of key cytokines, chemokines and inflammatory mediators would potentially lead to targeted antiviral therapies and would be a significant advance in the study of RSV pathogenesis.

Conclusion
This work demonstrates that clinical isolates of RSV are not homogeneous in their ability to induce specific cytokines. Screening of a relatively small number of clinical isolates resulted in the identification of strains, NH1067 and NH1125, with markedly different cytokine-inducing phenotypes. This work demonstrates the utility of investigating clinical isolates, whose naturally-occurring mutations result in distinct phenotypes. These data suggest that further investigation, particularly with the use of primary human cells (airway epithelial cells or PBMCs), of these and other clinical isolates of RSV may yield insights into pathogenesis and virulence.

Methods
Viruses and cells
HEp-2 (CCL-23) and A549 (CCL-185) cells were obtained from the American Type Culture Collection (Manassas, VA) and cultivated in EMEM with 10 % fetal bovine serum. HEp-2 cells were used in the initial propagation and titration of the clinical strains; A549 cells were used in the cytokine experiments described below. Clinical isolates were obtained from RSV-infected individuals as described previously from New Haven, Connecticut [12] and Dallas, Texas. Viruses used in this study were propagated from specimens submitted to the clinical (diagnostic) laboratory (in New Haven, CT and Dallas, TX). All specimens from which viruses were obtained were submitted as part of routine care. Only left over material was used for viral propagation. Collection of specimens from the Clinical Virology Laboratory at Yale-New Haven Hospital was approved by the Yale University Human Investigations Committee. The single isolate from Dallas, Texas was propagated from a de-identified clinical specimen obtained from the Clinical Microbiology Laboratory at Children’s Medical Center, Dallas. Collection and use of clinical isolates followed all institutional requirements and guidelines and was consistent with policies and regulations for the use of patient derived materials.

Isolates were plaque purified 3 times on HEp-2 cells. Working stocks were prepared using 30%-60% (w/v) non-continuous sucrose density centrifugation (SW-28, 28,000 rpm, 4°C for 90 minutes). The virus containing band at the 30%-60% interface was collected, distributed into aliquots, and stored at −80°C. Viral titers were determined using a plaque assay [45]. Plaques were detected with an immunohistochemical staining technique using either goat anti-RSV HRP-conjugated antibody (Fitzgerald Industries International, Acton, MA) or a primary anti-RSV antibody (palivizumab, MedImmune, Gaithersberg, MD) and secondary HRP conjugated anti-human antibody (Jackson ImmunoResearch Laboratories, Inc., West grove, PA). Viruses were inactivated by subjecting viral inoculums to 2 doses of 5,000 joules of ultraviolet (UV) light. UV-inactivation was confirmed by cell culture.

Cytokine assays
Monolayers of A549 cells were infected with sucrose-purified clinical isolates of RSV at the moi designated in the text. After 90 minutes of infection, the inoculum was removed, the cells were washed with serum-free media and fresh media (F-12 Kaighn’s modification) containing 5% FBS was added to the infected monolayers. For cytokine analysis, supernatants were collected, clarified by centrifugation, snap frozen in liquid nitrogen and stored at −80°C until the specific assay was performed. For the initial screening of clinical isolates, the concentration of IL-6 was determined by ELISA using the DuoSet Human IL-6 ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s specifications. Standard curves with known concentrations of IL-6 were performed for each assay. All samples were analyzed on the same ELISA plate to minimize technical bias and there were at least 3 biological replicates for each
measurement. For experiments that measured concentrations of IL-6 and CCL5, BioPlex assays were performed using Bio-Plex Pro™ with conjugated magnetic beads according to the manufacturer’s instructions. Cytokine data were analyzed using Bio-Plex Manager™ version 4.1.1 software.

**Real time PCR**
Total RNA was extracted from A549 cell monolayers using the RNeasy Mini kit and QIAshredder columns (QIAGEN, Valencia, CA) according to the manufacturer’s recommendations. RNA extracts were treated with RNase-free DNase I (Roche), then reverse transcribed with Moloney murine leukemia virus reverse transcriptase (New England BioLabs) with a primer specific for the genomic (negative-sense) copy of the RSV N gene, 5'-ATGGCTCTTAGAAAGTCT-3'. PCR amplification of cDNA was performed in a reaction mixture containing 5 μL cDNA template, forward (5'-CT GTCATCCAGCAATATCACTATTCA-3') and reverse (5'-GCACATCATAATTGGGAGTGTCA-3') primers at a concentration of 400 nM each, and 12.5 μL iQ SYBR Green Supermix (Bio-Rad) in a total volume of 25 μL. Reaction conditions were as follows: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. For cDNA standards, RNA was extracted from plaque-titered stocks of the laboratory reference B strain 8/60 using the QIAamp Viral RNA Mini Kit (Qiagen), reverse-transcribed as above, and serially diluted. RSV genomic RNA quantity in each sample was calculated in “pfu equivalents.”

**Viral genome sequencing, phylogenetic analysis and real time PCR**
Viral RNA was extracted from clarified supernatants or sucrose-purified virus using QIAamp® Viral RNA Mini kit (QIAGEN). Reverse transcriptase and PCR were performed as previously described [12]. Primers used for the sequencing of clinical isolates are listed in Additional file 1. For sequence of the ends of the viral genome, purified viral RNA was circularized by ligation using T4 RNA ligase (Epitect, Madison, WI) as described elsewhere [46]. Primers were designed (see Additional File 1) to span the region of the ligated ends. The exact nucleotide at the 3’ and 5’ ends were determined by comparison to available genome sequences. DNA sequencing of PCR products was performed by the McDermott Center Sequencing Core using Applied Biosystems Inc. (ABI) Big Dye Terminator 3.1 chemistry and analyzed on ABI capillary instruments. Sequence analysis including alignment and integration of contigs, sequence comparisons and alignments, and phylogenetic analysis were performed using DNASTAR Lasgene 8 software (MegAlign and Seqman).

**Additional file**

**Additional file 1**: Primers Used for Sequencing of the genome of RSV isolates.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
RL, RW, PP, JL, IL, CW, JSK identified and isolated clinical strains of RSV. RL, RW, IL performed cytokine assays. RL, PP, AS, JL, JSK participated in the sequencing and analysis of the RSV genomes. RL, RW carried out the viral replication assays. JSK conceived of the study, provided oversight for all aspects of the study and prepared the draft of the manuscript. All authors read and approved the final manuscript.

**Authors’ information**
RW current institution is The University of California San Francisco. IL current institution is Ben Gurion University, Beer Sheva, Israel. AS is an undergraduate student at Cornell University. JL is an undergraduate student at Texas A&M.

**Acknowledgements**
This work was supported, in part, by funds from the University of Texas Southwestern Medical Center and Children’s Medical Center Dallas. We are indebted to George Miller, M.D., John Enders Professor of Pediatrics, Epidemiology and Public Health and Molecular Biophysics and Biochemistry, Yale University School of Medicine for his support and critical review of the data. We thank Marie Landry, M.D., David Ferguson and the staff of the Clinical Virology Laboratory, YaleNew Haven Hospital (CT), and Chris Doern, Ph.D, Director, Clinical Microbiology, Children’s Medical Center for their assistance. We thank Benjamin Goldwater for his critical review of the manuscript.

**Author details**
1. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Yale University School of Medicine, New Haven, CT, USA. 4. The University of California San Francisco, San Francisco, CA, USA. 5. Ben Gurion University, Beer Sheva, Israel.

**Received: 10 February 2012 Accepted: 24 August 2012 Published: 10 September 2012**

**References**
1. Hall CB: Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001, 344(25):1917–1928.
2. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K: Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985, 151(4):626–633.
3. Peret TC, Hall CB, Hammond GW, Piedra PA, Storch GA, Sullender WM, Tsou C, Anderson LJ: Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis 2000, 181(6):1891–1896.
4. Zlateva KT, Lemey P, Moe E, Vandamme AM, Van Ranst M: Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol 2005, 79(14):9157–9167.
5. Zlateva KT, Lemey P, Vandamme AM, Van Ranst M: Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup A: positively selected sites in the attachment g glycoprotein. J Virol 2004, 78(9):4675–4683.
6. Tripp RA, Oshansky C, Alvarez R: Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2005, 2(2):147–149.
7. Miller AL, Bowlin TL, Lukacs NW: Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 2004, 189(8):1419–1430.
8. Kong X, San Juan H, Kumar M, Behera AK, Mohapatra A, Hellemann GR, Mane S, Lockey RF, Mohapatra SS: Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun 2003, 302:616–p. 622.
9. Hornsleth A, Klug B, Nir M, Johansen J, Hansen KS, Christensen LS, Larsen LB. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions. Pediatr Infect Dis J 1998, 17(1):1114–1121.

10. Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sanchez PJ, Ramilo O. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999, 18(2):115–122.

11. Hornsleth A, Loland L, Larsen LB. Cytokines and chemokines in respiratory secretion and severity of disease in infants with respiratory syncytial virus (RSV) infection. J Clin Virol 2001, 21(2):163–170.

12. Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 2002, 186(6):839–842.

13. Fletcher JN, Smyth RL, Thomas HM, Ashby D, Hart CA. Respiratory syncytial virus genotypes and disease severity among children in hospital. Arch Dis Child 1997, 76(7):508–511.

14. Gicera R, De Serres G, Tremblay M, Leblanc E, Bergeron MG, Dery J, Boivin G. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006, 193(1):54–58.

15. Venter PR, Spriens MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial virus subgroups A and B: extensive sequence divergence between antagonically related proteins. Proc Natl Acad Sci U S A 1997, 94(6):5652–5659.

16. Trento A, Gallano M, Vedola C, Carballal G, Garcia-Barreno B, Melero JA, Palomo C. Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. J Gen Virol 2003, 84(Pt 1):315–3120.

17. van Niekerk S, Venter M. Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa. J Virol 2011, 85(17):8789–8797.

18. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004, 17(2):165–181.

19. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 2003, 22(2 Suppl.):S6–S10. discussion S10-2.

20. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000, 48(3):237–247.

21. Garofalo RP, Haebeler H. Epithelial regulation of innate immunity to respiratory syncytial virus. Am J Respir Cell Mol Biol 2000, 23(5):581–585.

22. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, Ho SB, Peebles RS Jr. Differential immune responses and pulmonary pathophysiologoy are induced by two different strains of respiratory syncytial virus. Am J Pathol 2006, 169(3):977–986.

23. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VN, Huckabee MM, Newcomb DC, Buchholz UJ, Cowie JE Jr, Goleniowski K, Williams JV, Collins PL, Peebles RS Jr. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 2009, 83(9):4185–4194.

24. Villeneuve R, O'Donoghue D, Thavagnanam S, Touzet E, Smirnoff G, Heaney LG, McKenzie JP, Coyle PV, Shields MG, Power LP. Differential cytotoxicity and pathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary paediatric bronchial epithelial cells. Virol J 2011, 8:43.

25. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniowski K, Pretto C, Williams JV, Hotard A, Shemilt TP, Peebles RS Jr, Moore ML. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011, 85(12):7582–7593.

26. Haebeler HA, Takazawa R, Casola A, Brasier AR, Dieterich HJ, Van Rooijen N, Gatalica Z, Garofalo RP. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 2002, 186(6):1199–1206.

27. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001, 75(22):10730–10737.

28. Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Kapadia S, Treci K, Skoner DP. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol 2003, 64(3):338–344.

29. Gentile DA, Doyle WJ, Zeevi A, Pitcher O, Skoner DP. Cytokine gene polymorphisms moderate responses to respiratory syncytial virus in adults. Hum Immunol 2003, 64(1):93–98.

30. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ, CXC chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001, 2(8):732–738.

31. Saper T, Matthews S, Russell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJ. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998, 187(1):1921–1926.

32. Yeboey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998, 188(10):1967–1972.

33. Varga SM, Wissinger BL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol 2000, 165(11):4877–4895.

34. Tripp RA, Jones L, Anderson LJ. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol 2000, 74(13):6227–6229.

35. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karson RA, Collins PL, Kleeberger SR. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A 2005, 102(25):8966–8971.

36. Arnold R, Konig B, Wechau H, Konig W. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 2004, 330(2):384–397.

37. Whitehead SS, Firestone CY, Collins PL, Murphy BR. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998, 247(2):232–239.

38. Martinez I, Lombardia L, Garcia-Barreno B, Dominguez O, Melero JA. Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. J Gen Virol 2007, 88(Pt 2):570–581.

39. Jiang Z, Kuniimoto M, Patel JA. Autocrine regulation and controlled modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. J Virol 1998, 72(3):2496–2499.

40. Fasel M, Martus P, Hohne M, Wiedemann B, Hoff P, Schreier E, Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NSSA-ISR: a meta-analysis focused on geographical differences. Gut 2004, 53(3):1345–1351.

41. Dunfee RL, Thomas ER, Gory PR, Wang J, Taylor J, Kunstman K, Wollinsky SM, Gabuzda D. The HIV Env variant N283 enhances macrophage tropism and is associated with brain inflammation and dementia. Proc Natl Acad Sci U S A 2006, 103(15):15160–15165.

42. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swaeny DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005, 310(5745):77–80.

43. Hsiung GD, Fong CKY, Landry ML. Hsiung’s Diagnostic Virology. 4th edition. New York: Raven Press; 1994.

44. Kremp DL, Laminarde EW, Collins PL. Complete sequence of the RNA genome of pneumonia virus of mice (PVM). Virus Genes 2000, 20(2):237–249.